A Phase 2 interventional study of Placebo and CT-868 in Obesity, Overweight and Type 2 Diabetes Mellitus, sponsored by Carmot Therapeutics, Inc.. Completed at 5 sites in Mexico. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.
Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 14th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 2, and was the 3rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, Taiwan, United Kingdom
Ages 40+
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 300 across the 21 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Carmot Therapeutics, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Carmot Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
3 of the studies in Obesity by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT07499050Hoffmann-La RocheA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight | 2027-01-09 |
| NCT07589686Hoffmann-La RocheA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Obesity by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the placebo arm received volume- and regimen-matched placebo.
Drug: Placebo
Participants in the CT-868 1.75 mg arm received 1.0 mg/day for 2 weeks followed by 1.75 mg/day for the remaining treatment period.
Drug: CT-868
Participants in the CT-868 4.0 mg arm escalated through 1.0 mg/day for 2 weeks, 1.75 mg/day for 2 weeks, 2.5 mg/day for 4 weeks, 3.25 mg/day for 4 weeks, to 4.0 mg/day for the remaining 14 weeks.
Drug: CT-868
Participants self-injected once-daily subcutaneous volume- and regimen-matched placebo for 26 weeks.
Participants self-injected once-daily subcutaneous CT-868 for 26 weeks according to the randomized dose and regimen.
Change from Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 26
Time frame: Baseline and Week 26
Change from Baseline in HbA1c at Week 12
Time frame: Baseline and Week 12
Percentage of Participants Achieving HbA1c <5.7% at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants Achieving HbA1c ≤6.5% at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants Achieving HbA1c <7.0% at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percent Change from Baseline in Body Weight at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Absolute (kg) Change from Baseline in Body Weight at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants with ≥5% Body Weight Loss from Baseline at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants with ≥10% Body Weight Loss from Baseline at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants with ≥15% Body Weight Loss from Baseline at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants with ≥20% Body Weight Loss from Baseline at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Fasting Plasma Glucose at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Fasting Insulin at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Waist Circumference at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Hip Circumference at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Waist-to-Hip Ratio at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Waist-to-Height Ratio at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Body Mass Index (BMI) at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Total Cholesterol at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Triglycerides at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Low Density Lipoprotein (LDL) Cholesterol at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in High Density Lipoprotein (HDL) Cholesterol at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Apolipoprotein B at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Change from Baseline in Quantitative Insulin Sensitivity Check Index (QUICKI) at Weeks 12 and 26
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants with at Least One Treatment-Emergent Adverse Event
Time frame: From first dose of study drug until 4 weeks after the last dose of study drug (30 weeks)
Percentage of Participants with at Least One Hypoglycemic Event
Time frame: From first dose of study drug until 4 weeks after the last dose of study drug (30 weeks)
Percentage of Participants Testing Positive for Anti-Drug Antibodies to CT-868 at Baseline and Anytime Post-Baseline
Time frame: Baseline and Post-Baseline (up to 30 weeks)
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in Feb 2023, 12 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 12 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CT-868